236 related articles for article (PubMed ID: 21169248)
1. Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction?
LoRusso PM; Anderson AB; Boerner SA; Averbuch SD
Clin Cancer Res; 2010 Dec; 16(24):5956-62. PubMed ID: 21169248
[TBL] [Abstract][Full Text] [Related]
2. Trial design for evaluation of novel targeted therapies.
Farley J; Rose PG
Gynecol Oncol; 2010 Feb; 116(2):173-6. PubMed ID: 19853899
[TBL] [Abstract][Full Text] [Related]
3. Evaluating patient-centered outcomes in the randomized controlled trial and beyond: informing the future with lessons from the past.
Booth CM
Clin Cancer Res; 2010 Dec; 16(24):5963-71. PubMed ID: 21169249
[TBL] [Abstract][Full Text] [Related]
4. Translating clinical trials into meaningful outcomes.
LoRusso PM; Schnipper LE; Stewart DJ; Boerner SA; Averbuch SD; Wolf W
Clin Cancer Res; 2010 Dec; 16(24):5951-5. PubMed ID: 21169247
[TBL] [Abstract][Full Text] [Related]
5. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
6. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
7. Improving the design of phase II trials of cytostatic anticancer agents.
Stone A; Wheeler C; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
[TBL] [Abstract][Full Text] [Related]
8. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
Suman VJ; Dueck A; Sargent DJ
Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
[No Abstract] [Full Text] [Related]
9. Novel designs and end points for phase II clinical trials.
Adjei AA; Christian M; Ivy P
Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
[TBL] [Abstract][Full Text] [Related]
10. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
11. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
Gray R; Manola J; Saxman S; Wright J; Dutcher J; Atkins M; Carducci M; See W; Sweeney C; Liu G; Stein M; Dreicer R; Wilding G; DiPaola RS
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1966-9. PubMed ID: 16609005
[TBL] [Abstract][Full Text] [Related]
12. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
Takimoto CH
Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
[TBL] [Abstract][Full Text] [Related]
13. Early phase clinical trials in pediatric hematology and oncology.
Corbacioglu S
Klin Padiatr; 2012 Apr; 224(3):197-200. PubMed ID: 22511313
[TBL] [Abstract][Full Text] [Related]
14. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
[TBL] [Abstract][Full Text] [Related]
15. The use of genomics in clinical trial design.
Simon R
Clin Cancer Res; 2008 Oct; 14(19):5984-93. PubMed ID: 18829477
[TBL] [Abstract][Full Text] [Related]
16. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
17. Drug research: from the idea to the product.
Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
[TBL] [Abstract][Full Text] [Related]
18. Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT).
Booth CM; Calvert AH; Giaccone G; Lobbezoo MW; Eisenhauer EA; Seymour LK
Eur J Cancer; 2008 Jan; 44(1):25-9. PubMed ID: 17845846
[TBL] [Abstract][Full Text] [Related]
19. [Methodological approaches of clinical studies with targeted therapies].
Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
[TBL] [Abstract][Full Text] [Related]
20. Phase I trials as valid therapeutic options for patients with cancer.
Adashek JJ; LoRusso PM; Hong DS; Kurzrock R
Nat Rev Clin Oncol; 2019 Dec; 16(12):773-778. PubMed ID: 31477881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
